b
r
c
egfrmut
lung
adenocarcinoma
contain
subpopul
cell
undergon
epithelialtomesenchym
transit
grow
independ
egfr
kill
cancer
cell
need
novel
therapeut
approach
egfr
inhibitor
molecul
specif
express
cell
surfac
egfrindepend
egfrmut
cancer
cell
therapeut
target
found
mesenchym
egfrindepend
sublin
deriv
cell
egfrmut
lung
adenocarcinoma
cell
line
express
angiotensinconvert
enzym
greater
extent
parent
cell
also
express
least
partial
primari
egfrmut
lung
adenocarcinoma
examin
express
level
cancer
cell
much
higher
normal
lung
epitheli
cell
addit
develop
mous
monoclon
antibodi
mab
term
intern
cell
antibodydrug
conjug
consist
human
mab
base
potent
anticanc
drug
produc
could
effect
treatment
egfrmut
lung
adenocarcinoma
lung
adenocarcinoma
activ
mutat
epiderm
growth
factor
receptor
egfr
gene
heavili
depend
egfr
signal
surviv
prolifer
although
mani
tumor
initi
respond
well
egfr
tyrosin
kinas
inhibitor
tki
acquir
resist
nearli
alway
develop
averag
year
initi
tki
therapi
fewer
patient
acquir
resist
adenocarcinoma
cell
lose
origin
phenotyp
display
mesenchym
phenotyp
instead
indic
undergon
epitheli
mesenchym
transit
emt
previous
demonstr
three
egfrmut
lung
adenocarcinoma
cell
line
subpopul
cell
undergon
emt
surviv
independ
egfr
signal
although
cell
retain
egfr
mutat
parent
cell
sinc
egfrindepend
egfrmut
cancer
cell
never
undergo
apoptosi
egfr
inhibit
use
tki
cell
appear
lie
root
tki
resist
develop
monoclon
antibodi
mab
bind
membran
protein
mesenchym
egfrmut
cancer
cell
intern
cell
essenti
antibodydrug
conjug
adc
develop
conjug
anticanc
agent
mab
could
promis
therapeut
option
tkiresist
egfrmut
lung
cancer
previous
develop
effici
screen
method
select
mab
intern
target
cell
screen
system
recombin
protein
term
consist
diphtheria
toxin
dt
lack
receptorbind
domain
contain
domain
streptococc
protein
g
play
critic
role
conjug
intern
function
like
adc
induc
extens
cell
death
target
cell
angiotensinconvert
enzym
catalyz
convers
angiotensin
ii
angiotensin
angiotensin
ii
major
effector
molecul
convent
reninangiotensin
system
implic
pathogenesi
cardiovascular
disord
includ
hypertens
atherosclerosi
myocardi
infarct
wherea
product
angiotensin
thought
prevent
detriment
effect
angiotensin
ii
respiratori
organ
receptor
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sarscov
howev
also
shown
attenu
inflamm
andor
acut
lung
injuri
caus
sarscov
infect
influenza
viru
infect
etiolog
mainli
inhibit
angiotensin
iimedi
nfkb
signal
expect
fact
act
receptor
sarscov
report
local
apic
membran
respiratori
epitheli
cell
includ
alveolar
epithelia
far
awar
studi
avail
express
egfrmut
lung
adenocarcinoma
addit
seem
express
low
level
normal
lung
lung
cancer
tissu
accord
human
protein
atla
studi
demonstr
tkiresist
sublin
deriv
egfrmut
cell
express
much
higher
level
parent
cell
primari
egfrmut
lung
adenocarcinoma
tissu
contain
cancer
cell
express
greater
degre
normal
alveolar
epitheli
cell
addit
develop
new
mous
mab
intern
target
cell
adc
consist
human
mab
base
potent
anticanc
drug
produc
new
adc
could
effect
treatment
egfrmut
lung
adenocarcinoma
contain
tkiresist
cell
experiment
procedur
approv
institut
review
board
sapporo
medic
univers
three
egfrmut
lung
adenocarcinoma
cell
line
del
del
purchas
american
type
cultur
collect
manassa
va
usa
previous
clone
extens
analyz
egfrtki
resist
sublin
three
egfrmut
cell
line
gefitinibresist
gr
wr
cell
note
gefitinib
firstand
thirdgener
egfr
tki
respect
cell
mous
myeloma
cell
japanes
collect
research
bioresourc
cell
bank
osaka
japan
cultur
supplement
vv
super
low
iggfb
hyclon
thermo
fisher
scientif
japan
yokohama
japan
vv
streptomycinpenicillinglutamin
solut
thermo
fisher
scientif
co
also
examin
primari
human
lung
hul
cell
normal
human
alveolar
epitheli
cell
deriv
three
individu
maintain
bronchial
epitheli
cell
growth
medium
lonza
japan
tokyo
japan
express
written
inform
consent
obtain
patient
immun
balbc
mous
cell
describ
previous
two
day
final
inject
cell
mous
sacrif
splenocyt
fuse
cell
use
polyethylen
glycol
hybridoma
grown
confluenc
cultur
supernat
fluid
polyclon
antibodi
produc
test
antibodi
intern
supernat
well
incub
togeth
micropl
room
temperatur
min
form
conjug
cell
ad
well
concentr
cell
well
incub
h
number
viabl
cell
treatment
estim
use
assay
roch
diagnost
indianapoli
usa
hybridoma
induc
extens
cell
death
select
clone
limit
dilut
biotinyl
surfac
cell
use
biotinyl
kit
thermo
fisher
scientif
cell
membran
solubil
describ
previous
mous
mab
term
develop
studi
control
mous
bd
bioscienc
tokyo
japan
use
immunoprecipit
follow
method
use
describ
previous
mab
incub
togeth
room
temperatur
min
gener
conjug
cell
seed
incub
presenc
conjug
h
viabil
cancer
cell
assess
use
assay
effici
format
conjug
use
quantiti
mab
requir
suffici
format
conjug
concentr
test
theori
conjug
consist
one
mab
molecul
kda
two
kda
tumor
tissu
obtain
five
egfrmut
lung
adenocarcinoma
patient
oper
sapporo
medic
univers
hospit
august
januari
patient
group
includ
man
four
women
median
age
year
rang
year
tabl
tumor
slide
stain
hematoxylin
eosin
h
e
review
one
author
ys
verifi
diagnosi
tumor
express
egfr
protein
high
level
immunohistochemistri
data
shown
egfr
mutat
identifi
tumor
describ
tabl
immunohistochem
stain
perform
formalinfix
paraffinembed
ffpe
primari
egfrmut
lung
adenocarcinoma
tissu
section
select
repres
ffpe
tissu
block
patient
contain
noncancer
cancer
tissu
precis
evalu
express
region
whole
tissu
section
retriev
use
use
primari
antibodi
mgml
immunohistochem
stain
conduct
use
leica
bondmax
leica
confirm
immunohistochemistri
express
perform
detect
strong
membran
express
small
intestin
epithelia
posit
control
data
shown
membran
stain
score
base
intens
none
weak
intermedi
strong
proport
carcinoma
cell
express
molecul
none
use
allr
score
method
cell
plate
plate
grown
h
transfect
accutarget
neg
control
nc
sirna
duplex
two
accutarget
predesign
sirna
duplex
target
name
sirna
respect
studi
bioneer
daejeon
korea
use
lipofectamin
rnaimax
reagent
optimem
invitrogen
thermo
fisher
scientif
accord
manufactur
recommend
downregul
target
gene
express
verifi
flow
cytomet
use
facscalibur
bd
bioscienc
mab
total
cellular
rna
extract
rneasi
mini
kit
qiagen
valencia
ca
usa
mg
total
rna
revers
transcrib
cdna
use
revertra
ace
qpcr
rt
master
mix
gdna
remov
toyobo
osaka
japan
accord
manufactur
instruct
realtim
pcr
perform
use
combin
quantitect
primer
assay
qiagen
thunderbird
sybr
qpcr
mix
toyobo
lightcycl
nano
roch
appli
scienc
amount
bactin
mrna
sampl
use
standard
quantiti
mrna
rel
mrna
express
level
parent
cell
cell
calcul
differ
threshold
cycl
compar
ddc
method
present
averag
triplic
experi
also
conduct
convent
rtpcr
express
use
pcr
primer
differ
cell
viabil
nc
sirna
sirna
transfect
cell
treat
conjug
evalu
pair
ttest
differ
cell
viabil
parent
cell
treat
conjug
express
level
mrna
parent
cell
evalu
unpair
ttest
pvalu
less
consid
signific
statist
calcul
perform
jmp
softwar
jmp
window
version
sa
institut
japan
tokyo
japan
clone
hybridoma
well
conjug
substanti
decreas
viabil
cell
base
premis
cell
viabil
well
reflect
effici
intern
conjug
cell
consequ
establish
hybridoma
secret
mab
recogn
protein
kda
reduc
condit
fig
mass
spectrometri
identifi
possibl
candid
kda
molecul
fig
express
target
protein
clearli
reduc
rna
interfer
fig
collect
indic
mab
term
bound
addit
although
conjug
substanti
induc
cell
death
nc
sirnatransfect
cell
expect
cell
becam
markedli
resist
treatment
surviv
knock
sirna
fig
cell
clearli
express
wherea
parent
cell
bare
express
molecul
protein
mrna
level
fig
b
addit
parent
cell
significantli
resist
conjug
cell
fig
support
concept
express
parent
cell
limit
find
led
us
examin
whether
extent
tkiresist
mesenchym
egfrmut
cell
parent
cell
express
howev
express
tkiresist
parent
cell
fig
egfrmut
lung
adenocarcinoma
examin
contain
carcinoma
cell
show
membran
express
tabl
fig
hand
normal
bronchial
alveolar
epitheli
cell
stain
neg
bare
express
fig
although
cell
previous
report
express
molecul
moreov
cell
normal
human
alveolar
epitheli
cell
bare
express
flow
cytomet
fig
although
carcinoma
cell
express
even
tumor
express
level
egfrmut
carcinoma
cell
seem
much
higher
normal
lung
epitheli
cell
develop
new
mous
mab
intern
cell
found
express
greater
degre
tkiresist
egfrmut
cell
emt
phenotyp
parent
cell
adc
consist
human
mab
base
potent
anticanc
drug
produc
new
adc
could
induc
cell
death
effici
cancer
cell
express
cell
cell
mesenchym
egfrmut
lung
adenocarcinoma
sublin
express
could
see
promis
therapeut
target
fulli
erad
egfrmut
cancer
cell
unfortun
neither
two
sublin
express
howev
also
demonstr
studi
egfrmut
lung
adenocarcinoma
tissu
mostli
express
least
partial
express
level
carcinoma
cell
appear
higher
normal
lung
bronchial
alveolar
epitheli
cell
find
suggest
adc
incorpor
mab
could
induc
cell
death
egfrmut
cancer
cell
effici
normal
lung
epithelia
remain
establish
whether
egfrmut
lung
cancer
cell
resist
egfrtki
surviv
tki
treatment
mention
earlier
lungprotect
molecul
sarscov
influenza
virusinduc
acut
lung
injuri
thu
seem
danger
suppress
function
lung
howev
shown
egfrmut
lung
adenocarcinoma
mostli
contain
cancer
cell
express
greater
extent
normal
lung
epithelia
mesenchym
tkiresist
cell
strongli
express
molecul
suggest
adc
incorpor
mab
could
anoth
therapeut
option
egfrmut
lung
cancer
might
abl
suppress
growth
none
author
present
studi
conflict
interest
declar
